ASX Healthcare Stock Achieving key Strategic Milestones
Pacific Edge has made strategic gains in its effort to restore Medicare coverage for Cxbladder. Despite lower volumes in the US, key evidence and policy milestones suggest momentum is building. The coming Medicare meeting and appeal hearings are crucial turning points.
Pacific Edge Limited (ASX: PEB)
Pacific Edge Limited (ASX: PEB) shared growth toward restoring Medicare coverage for its Cxbladder tests in their most recent quarterly report. The company highlighted an upcoming Medicare Administrative Contractor meeting on 20 February which is important because these meetings often precede new or revised coverage decisions. A positive outcome could lead to a new Local Coverage Determination, which would make Medicare reimbursement more predictable for Cxbladder.
PEB also confirmed that a real-world study showing Cxbladder Triage’s clinical value has been accepted for publication and strengthening the evidence base used in Medicare discussions. This is important because stronger clinical proof can help persuade decision makers that the test is medically necessary. Also, Pacific Edge noted progress in Medicare appeals for denied Cxbladder Triage claims with the first hearing scheduled for 24 February, suggesting the company is actively challenging coverage denials.
Total test volume fell by 13.4% to 5,446 in Q3 FY26 mainly due to seasonal holiday slowdowns and ongoing reimbursement uncertainty affecting demand in the US. US volumes dropped almost 20% whereas APAC grew by 9.7% to 1,443 tests driven by higher commercial testing in that region. This suggests stronger demand where reimbursement and commercial pathways are more stable.
Positive momentum also includes endorsement from a major US diagnostic intelligence provider covering over 44 million lives indicating broader recognition of the test’s clinical value. Through a new chair in place, PEB aims to convert these milestones into durable Medicare policy, which would significantly improve long term revenue visibility.
(Source: Company Announcements)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
